Discussion about this post

User's avatar
Ali Jacobs's avatar

Hi Juliet,

Another exquisite and candid piece from you - absorbing and moving reading.

I am here, twenty years after my blood cancer, because of trials.

There was the “spin to win” one at the start that determined which chemotherapy regime I’d be on for the next six months. I got the standard, incredibly harsh one for that time, rather than the gentler Spanish protocol that is now not just widely used and saving countless lives, but transforming how APML patients exist during the treatment. I was also in one of the first patient cohorts to automatically receive ATRA - the silver bullet treatment for APML people that takes us into an initial remission.

Then during my third cycle, alongside the constant chemo (for that cycle I was on a constant chemo drip for six days, no break), I had the luck to also be a trial patient on MiloTarg - which does have a massively long official name, but all I needed to understand was that it specifically zoomed in on anything that looked like a baddie in my bloodstream.

A year later and well into my remission, I attended a Leukaemia Care day, where I heard from a number of experts and talked to other people who had been through blood cancer or still had it. My heart still breaks when I remember the older man who had not been able to access MiloTarg because of the health trust her was under among other factors, and was facing limited treatment avenues.

Cancer’s not just a game of chance with our bodies and how we respond to treatments, but also in terms of access and suitability.

But we always need to say yes to new trials and treatments. As you said so eloquently, we’re not simply playing the role of a guinea pig. We are science.

Z O E   B E R K E L E Y's avatar

I’m sorry you have to be, but thank you for being science x

2 more comments...

No posts

Ready for more?